相似文献
1
Systemic Therapy Development in Von Hippel-Lindau Disease: An Outsized Contribution from an Orphan Disease.
Cancers (Basel). 2022 Oct 28;14(21):5313. doi: 10.3390/cancers14215313.
2
VON HIPPEL-LINDAU DISEASE: Update on Pathogenesis and Systemic Aspects.
Retina. 2019 Dec;39(12):2243-2253. doi: 10.1097/IAE.0000000000002555.
3
Extraneuraxial hemangioblastoma: A clinicopathologic study of 10 cases with molecular analysis of the VHL gene.
Pathol Res Pract. 2018 Aug;214(8):1156-1165. doi: 10.1016/j.prp.2018.05.007. Epub 2018 May 29.
4
The impact of molecular genetic analysis of the VHL gene in patients with haemangioblastomas of the central nervous system.
J Neurol Neurosurg Psychiatry. 1999 Dec;67(6):758-62. doi: 10.1136/jnnp.67.6.758.
5
Retinal hemangioblastoma: prevalence, incidence and frequency of underlying von Hippel-Lindau disease.
Br J Ophthalmol. 2018 Jul;102(7):942-947. doi: 10.1136/bjophthalmol-2017-310884. Epub 2017 Sep 28.
6
De novo VHL germline mutation detected in a patient with mild clinical phenotype of von Hippel-Lindau disease.
J Neurosurg. 2014 Aug;121(2):384-386. doi: 10.3171/2014.2.JNS131190. Epub 2014 Mar 28.
7
A meta-analysis of different von Hippel Lindau mutations: are they related to retinal capillary hemangioblastoma?
Mol Genet Genomics. 2022 Nov;297(6):1615-1626. doi: 10.1007/s00438-022-01940-z. Epub 2022 Aug 25.
8
Genetic study of a large Chinese kindred with von Hippel-Lindau disease.
Chin Med J (Engl). 2004 Apr;117(4):552-7.
9
A case of von Hippel-Lindau disease with bilateral pheochromocytoma, renal cell carcinoma, pelvic tumor, spinal hemangioblastoma and primary hyperparathyroidism.
Endocr J. 2002 Apr;49(2):181-8. doi: 10.1507/endocrj.49.181.
10
Variable response of CNS hemangioblastomas to Pazopanib in a single patient with von Hippel-Lindau disease: Case report.
J Clin Neurosci. 2018 Apr;50:154-156. doi: 10.1016/j.jocn.2018.01.040. Epub 2018 Feb 1.
引用本文的文献
1
Von Hippel-Lindau Disease : A Comprehensive Review of Diagnosis, Genetics, Clinical Challenges, and Surveillance.
J Korean Neurosurg Soc. 2025 May;68(3):338-349. doi: 10.3340/jkns.2025.0018. Epub 2025 Mar 20.
2
Stereotactic radiosurgery in the management of central nervous system hemangioblastomas: a systematic review and meta-analysis.
Neurosurg Rev. 2025 Mar 17;48(1):303. doi: 10.1007/s10143-025-03454-9.
3
Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond.
Future Oncol. 2024;20(18):1251-1266. doi: 10.2217/fon-2023-0679. Epub 2024 Apr 19.
本文引用的文献
1
Belzutifan, a Potent HIF2α Inhibitor, in the Pacak-Zhuang Syndrome.
N Engl J Med. 2021 Nov 25;385(22):2059-2065. doi: 10.1056/NEJMoa2110051.
2
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
N Engl J Med. 2021 Nov 25;385(22):2036-2046. doi: 10.1056/NEJMoa2103425.
3
MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma.
Expert Opin Investig Drugs. 2021 May;30(5):495-504. doi: 10.1080/13543784.2021.1925248. Epub 2021 May 20.
4
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.
Nat Med. 2021 May;27(5):802-805. doi: 10.1038/s41591-021-01324-7. Epub 2021 Apr 22.
5
The von Hippel-Lindau Tumor Suppressor Gene: Implications and Therapeutic Opportunities.
Cancer J. 2020 Sep/Oct;26(5):390-398. doi: 10.1097/PPO.0000000000000480.
6
Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease.
World J Urol. 2021 Jul;39(7):2409-2415. doi: 10.1007/s00345-020-03441-3. Epub 2020 Sep 16.
7
HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma.
Clin Cancer Res. 2020 Feb 15;26(4):793-803. doi: 10.1158/1078-0432.CCR-19-1459. Epub 2019 Nov 14.
8
HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species.
Sci Signal. 2019 Oct 1;12(601):eaay0482. doi: 10.1126/scisignal.aay0482.
9
3-[(1,2,3)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma.
J Med Chem. 2019 Aug 8;62(15):6876-6893. doi: 10.1021/acs.jmedchem.9b00719. Epub 2019 Jul 8.
10
Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial.
Lancet Oncol. 2018 Oct;19(10):1351-1359. doi: 10.1016/S1470-2045(18)30487-X. Epub 2018 Sep 17.
Zotero 插件